FGFR1 and renal cell carcinoma: Sorafenib (Nexavar®). Sorafenib is an inhibitor of VEGFR2/3, PDGFR, KIT, FGFR-1, RAF and RET, approved by the U.S. FDA for the treatment of unresectable HCC and advanced RCC [815].